Trial Profile
An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease, Followed by an Extension Phase to Provide Canakinumab to Study Patients Until it is Approved and Marketed in Japan
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Cryopyrin-associated periodic syndromes
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Sep 2022 Interim results assessing safety and effectiveness of canakinumab in patients in Japan with cryopyrin-associated periodic fever syndrome (CAPS), including familial cold auto-inflammatory syndrome, Muckle-Wells syndrome, and neonatal onset multisystem inflammatory disease, published in the Clinical and Experimental Rheumatology.
- 14 Dec 2016 Results assessing safety and efficacy published in the Clinical and Experimental Rheumatology.
- 19 Nov 2014 New trial record